ライフサイエンスコーパス: passive immunization

1 V-1 is a major challenge for both active and passive immunization.

2 to a more potent reagent for gene therapy or passive immunization.

3 the use of anti-E2 antibodies as a means of passive immunization.

4 protected mice from a lethal VV challenge by passive immunization.

5 domain Abs have reinvigorated the concept of passive immunization.

6 T-helper cell subset 1 response and enables passive immunization.

7 offers an attractive alternative option for passive immunization.

8 antibodies for virus following active versus passive immunization.

9 transplantation can be reduced by aggressive passive immunization.

10 of infants were protected through active or passive immunization.

11 medical interventions, including active and passive immunization.

12 ced by allergen-specific immunotherapy or by passive immunization.

13 more effective immunogens and antibodies for passive immunization.

14 ization, HSV-1 shedding, and latency through passive immunization.

15 mmunomodulatory effects as well as providing passive immunization.

16 cued spatial reference memory deficits after passive immunization.

17 IgG-FcgammaR interactions during active and passive immunization.

18 otected against systemic GAS challenge after passive immunization.

19 apsule is a potential therapeutic target via passive immunization.

20 prevention of viral acquisition by active or passive immunization.

21 uction before initiating a 12 week course of passive immunization.

22 rgy following prophylactic, therapeutic, and passive immunizations.

23 human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the preven

24 Unlike passive immunization, active immunization, which is the

25 Our data support a mechanism by which passive immunization acts centrally to stimulate microgl

26 ugh infections within 3 months occur despite passive immunization, affecting 11% in this series; howe

27 Passive immunization against beta-amyloid (Abeta) has be

28 rides, an iron scavenging protein, isdB, and passive immunization against clumping factor A and lipot

29 We hypothesized that passive immunization against cryptosporidiosis could be

30 opes on defined antigens may provide optimal passive immunization against cryptosporidiosis.

31 Passive immunization against GPI reduced the number of i

32 utralizing antibodies that could be used for passive immunization against H5N1 virus or as guides for

33 sCD4-17b has potential utility for passive immunization against HIV-1 in several contexts,

34 antibodies (bnAbs) are crucial for effective passive immunization against infectious diseases as prot

35 n-sensitive P23 epitopes may have utility in passive immunization against murine C. parvum infection.

36 activates primary mouse neutrophils ex vivo Passive immunization against NeSt1 decreases pro-interle

37 monoclonal neutralizing antibody (MPV.A4) by passive immunization against papillomavirus infections a

38 D, we investigated the potency of active and passive immunization against the conserved microbial sur

39 Therefore, we explored the effect of passive immunization against the CT of alpha-syn in the

40 Herein, we demonstrate that passive immunization against the Vbeta8-targeting SAg st

41 tralizing antibodies (nAbs), applied through passive immunization, also provide broad and complete pr

42 Passive immunization altered the growth and vascularizat

43 Ab has an important potential in therapeutic passive immunization and could help HIV-1 infected patie

44 he importance of the antibody format in oral passive immunization and encourage future expression of

45 Here, we review the precedent for passive immunization and lessons learned from using anti

46 such infection that may be prevented by oral passive immunization and might avert recurrent economic

47 imely, given recent progress with active and passive immunization and novel approaches to HIV-1 cure.

48 app = 200 nM) was tested in a mouse model of passive immunization and subsequent mole-equivalent chal

49 man IsdB-specific antibodies also blunt IsdB passive immunization, and additional SA vaccines are sus

50 uorescence assays, growth inhibition assays, passive immunizations, and active immunizations indicate

51 However, traditional passive immunization approaches carry the risk of Fcgamm

52 fic antibodies, acquired by either active or passive immunization, are sufficient to protect against

53 We demonstrate that HCV can be blocked by passive immunization, as well as showing that a recombin

54 noculation all showed protective activity in passive immunization assays.

55 d; adjunctive therapies (e.g. phage therapy, passive immunization, augmentation of cell mediated bact

56 thermore, when MIP-2 was depleted in vivo by passive immunization, bleomycin-induced pulmonary fibros

57 Oral feed-based passive immunization can be a promising strategy to prol

58 Here we show that elements of active and passive immunization can be combined to create an effect

59 Our findings demonstrate that passive immunization can be used as a model to evaluate

60 -CelTOS responses elicited by vaccination or passive immunization can inhibit sporozoite and ookinete

61 Our results suggest that passive immunization can reduce VAbeta levels, and modul

62 ed by active immunization or administered by passive immunization confer protection against S. aureus

63 us and vaccine-heterologous strains, whereas passive immunization confers only vaccine-homologous pro

64 To determine if passive immunization could decrease the incidence or sev

65 Thus, anti-gB passive immunization decreased fetal infection and intra

66 Passive immunization did not reduce transmission from in

67 iments to supplement the 14-3-3z antibody by passive immunization did not suppress arthritis.

68 However, passive immunization did prevent mortality from pneumoni

69 mited the study's ability to address whether passive immunization diminishes perinatal transmission.

70 n, highlighting their utility for evaluating passive immunization efficacy.

71 For passive immunization efforts, nanobodies have size and c

72 serum is sufficient to confer protection, a passive immunization experiment using pooled nHgbA antis

73 In addition, passive immunization experiments demonstrated that antib

74 virus (ZEBOV) have been successfully used in passive immunization experiments in rodent models, but h

75 This was confirmed by passive immunization experiments in which the protective

76 al passive immunity in fish and fish-to-fish passive immunization experiments supports the concept of

77 In passive immunization experiments using challenge with wi

78 isms underlying host resistance, a series of passive immunization experiments were carried out using

79 To test this hypothesis, passive immunization experiments were carried out with n

80 equencing, C2C12 mouse myotube cultures, and passive immunization experiments.

81 ersies and summarize active-immunization and passive-immunization experiments in nonhuman primates th

82 om a lethal intranasal challenge with WU2 in passive-immunization experiments in which 10 mug of the

83 only a subset of G(C) MAbs protected mice in passive-immunization experiments, while some nonneutrali

84 ntibodies (mAbs) has re-ignited the field of passive immunization for HIV-1 prevention.

85 eenth century, but the full potential to use passive immunization for infectious diseases has yet to

86 During studies of passive immunization for treatment of murine cryptococco

87 d subcutaneously alone and in combination as passive immunization for young women in South Africa.

88 However, the role of HPV-specific passive immunization from mother to neonate is nearly un

89 Passive immunization has been successfully employed for

90 soluble Abeta and tau levels after active or passive immunization in advanced aged 3xTg-AD mice that

91 omer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau

92 Using passive immunization in mice, the O:4-specific antibodie

93 se and prevented latency following active or passive immunization in preclinical studies.

94 Recommendations for using passive immunization in the general population or for th

95 l likely shape efforts to develop active and passive immunization interventions in response to the re

96 But most current strategies for passive immunization involve injection of antibodies for

97 As a result, passive immunization is an appropriate therapeutic optio

98 Consequently, passive immunization is being considered for treating Al

99 ocked TIGR4 adhesion in vitro and, following passive immunization, it protected mice against challeng

100 c antibodies in both the sera and lungs, and passive immunization led to the reduction of B. bronchis

101 a longer period of active immunotherapy, or passive immunization, may be required to provide suffici

102 enal disease is prevented in both active and passive immunization models by antigen-specific IgG1; ot

103 We have studied active and passive immunization models in mice to approach these is

104 and Thioflavin-S positive plaque load after passive immunization of 5XFAD mice.

105 Passive immunization of animals with a soluble TNF recep

106 Passive immunization of animals with anti-IL-12 serum i.

107 Passive immunization of B. burgdorferi-infected SCID mic

108 o the control normal mouse immunoglobulin G, passive immunization of BALB/c mice with MAb MoPn-23 res

109 Passive immunization of BALB/c mice with serum IgG again

110 Passive immunization of DENV-infected mice with polyclon

111 Passive immunization of hamsters with a mixture of toxin

112 culture systems or studies of protection by passive immunization of human liver chimeric mice offer

113 In addition, passive immunization of mice demonstrated that antibody

114 n of rheumatoid arthritis (RA) by active and passive immunization of mice results in the development

115 Passive immunization of mice with a goat antiserum raise

116 Passive immunization of mice with anti-dPNAG-DT rabbit s

117 t, when performed during progression of HUS, passive immunization of mice with anti-Stx2 antibody pre

118 The passive immunization of mice with rabbit antimurine MCP-

119 Passive immunization of mice with rabbit antiserum confe

120 Active and passive immunization of mice with recombinant Arp or Arp

121 Passive immunization of mice with this MAb resulted in r

122 Passive immunization of murine models of Alzheimer disea

123 otects against influenza challenge following passive immunization of naive mice.

124 Passive immunization of naive, ablated mice with sera or

125 We used passive immunization of neonatal piglets (as a surrogate

126 Furthermore, passive immunization of NSCLC tumor-bearing mice with ne

127 ight be paired with antibiotic treatment for passive immunization of patients suffering from P. aerug

128 different HIV-1 isolates, and used this for passive immunization of pig-tailed macaques.

129 Passive immunization of pregnant women with primary HCMV

130 Passive immunization of rabbits with M131 administered i

131 Passive immunization of susceptible and resistant mouse

132 This report examines the effects of chronic, passive immunization on VAbeta and microhemorrhage in PD

133 l for prophylaxis against HIV-1 infection by passive immunization or gene therapy.

134 ns of ETA, may have therapeutic potential in passive immunization or topical treatment of burn patien

135 from nasopharyngeal infection; however, only passive immunization, or vaccination with inactive SpeA,

136 Abeta monoclonal antibody (mAb) effective in passive immunization paradigm.

137 red to controls (5.64; P = 0.0480), and both passive immunizations (PLY = 31.34% loss of retinal func

138 This compensating effect was blocked by passive immunization pretreatment with the monoclonal Ig

139 HIV from infecting target cells and, through passive immunization, protect animals and humans from in

140 ions and to maximize antibody production and passive immunization protocols are being devised.

141 thers have demonstrated that both active and passive immunizations reduce Tau pathology and prevent c

142 We found that both active and passive immunization reduced corneal pathology scores af

143 Passive immunization reduced the burden of acute pneumon

144 se combinations might be sought in active or passive immunization regimes.

145 s to examine pathological outcomes following passive immunization, sequential cross-infection, or vac

146 epithelial neutrophil activating protein by passive immunization significantly attenuated neutrophil

147 Moreover, active or passive immunization significantly reduced S. aureus col

148 Both active and passive immunization strategies against Staphylococcus a

149 nt, identification of immune correlates, and passive immunization strategies for pertussis.

150 with a CD4+ T-cell count of <200 cells/muL, passive immunization strategies need to be explored to p

151 Active and passive immunization strategies targeting the CPs protec

152 efore increase the potency and durability of passive immunization strategies to prevent HIV-1 infecti

153 s to date have focused on the development of passive immunization strategies to prevent or treat diss

154 timal FcgammaR interactions in the design of passive immunization strategies.

155 een obtained with both probiotic therapy and passive immunization strategies.

156 essed cohorts that need novel vaccination or passive immunization strategies.

157 A passive immunization strategy for treating Ebola virus i

158 e of antibody preparations as a prophylactic passive immunization strategy in large populations.

159 c principles and scientific premises for the passive immunization strategy, including existing and em

160 over, vaccine-induced IgGs were purified for passive immunization studies and for in vitro experiment

161 Passive immunization studies are similarly hindered by t

162 Passive immunization studies demonstrated that productio

163 Both active and passive immunization studies have shown that antibodies

164 Previous passive immunization studies have suggested that the C-t

165 We addressed this issue in a series of passive immunization studies in Fischer 344 (F344) rats.

166 In addition, passive immunization studies showed that specific antibo

167 However, passive immunization studies suggested that protection r

168 binations can be validated in vivo in future passive immunization studies using the SHIV challenge mo

169 Passive immunization studies, including a recent one by

170 In both active and passive immunization studies, Osp C (N40) antiserum fail

171 igation of anti-NHR mAbs in nonhuman primate passive immunization studies.

172 ccine design, our data have implications for passive-immunization studies in countries where clade C

173 The success of passive immunization suggests that immunoglobulin (Ig)-b

174 psular polysaccharide from A. baumannii as a passive immunization target.

175 uggest the potential of combining active and passive immunization targeting different immunologic mec

176 Active or passive immunizations targeting Abeta are therefore of g

177 clinical studies demonstrate that active and passive immunizations targeting alpha-syn partially amel

178 ct against S. aureus infection of active and passive immunization that targeted 3 proteins involved i

179 One day after passive immunization, the animals were challenged i.p. w

180 (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies.

181 ely developed is immunotherapy-specifically, passive immunization through administration of exogenous

182 nfants at high risk of severe RSV disease is passive immunization through monoclonal antibodies.

183 One approach is passive immunization through the administration of antib

184 and PG16-iMab, are promising candidates for passive immunization to prevent HIV-1 infection.

185 in the presence of maternal immunity or upon passive immunization to rabies virus with the pSG5rab.gp

186 mune evasion tactics of the VoC, we utilized passive immunization to study the effect of early-pandem

187 sceptible populations are often compromised, passive immunization treatments using broadly neutralizi

188 e use this model to test our hypothesis that passive immunization using a single neutralizing monoclo

189 Passive immunization using Abeta-specific antibodies has

190 n the absence of an effective HIV-1 vaccine, passive immunization using broadly neutralizing Abs or A

191 of FcRn-transported IgG was demonstrated by passive immunization using herpes simplex virus-2 (HSV-2

192 Here, we utilized passive immunization using human convalescent plasma (HC

193 We have recently reported that passive immunization using monoclonal antibody M131 conv

194 Passive immunization using purified IgG from rabbits imm

195 tly, for the first time, we demonstrate that passive immunization using the antibody NT4X is therapeu

196 -influenza treatments are acutely needed and passive immunizations using broadly neutralizing anti-in

197 In contrast to systemic passive immunization, we observed markedly reduced (>/=8

198 r, virus isolated from 1 mouse 3 weeks after passive immunization with 13.2 mg/kg antibody proved res

199 Passive immunization with 2B11 increased neutrophil infi

200 e protected against lethality by intravenous passive immunization with a CPB antibody prior to intrag

201 Thus, passive immunization with a monoclonal neutralizing anti

202 Passive immunization with a rabbit antiserum against dLO

203 als, no safety concerns were identified with passive immunization with a single bNAb (VRC01).

204 Our findings suggest passive immunization with a single monoclonal neutralizi

205 Passive immunization with Ab doses resulting in serum Ig

206 to Abp2D(RBD) vaccination, demonstrate that passive immunization with Abp2D(RBD)-immune serum transf

207 Passive immunization with Abs against whole C. parvum or

208 Active or passive immunization with alpha-toxin toxoid could prote

209 vent or treat AD, we compared the effects of passive immunization with an anti-Abeta42 mAb, an anti-A

210 laboratory has previously demonstrated that passive immunization with an anti-tau antibody, HJ8.5, d

211 Passive immunization with an antibody directed against t

212 Passive immunization with an antibody directed to an epi

213 e protected against lethality by intravenous passive immunization with an epsilon toxin antibody prio

214 ion with the amyloid beta (Abeta) protein or passive immunization with anti-Abeta antibodies has bene

215 protein transgenic mice have suggested that passive immunization with anti-Abeta antibodies may clea

216 Finally, the efficacy of passive immunization with anti-Abeta antibodies on the c

217 Passive immunization with anti-amyloid-beta peptide (Abe

218 Importantly, passive immunization with anti-Ftr1p immune sera protect

219 Lastly, passive immunization with anti-OmpA MAbs did not confer

220 ction and therefore may benefit greatly from passive immunization with anti-spike monoclonal antibodi

221 Passive immunization with anti-Sse antiserum also signif

222 Passive immunization with anti-tau monoclonal antibodies

223 Passive immunization with antibodies against the envelop

224 Following passive immunization with antibody, no further adaptive

225 To evaluate the effect of passive immunization with anticapsular antibodies on nas

226 Passive immunization with antisera to these antigens is

227 Passive immunization with antiserum to CP5-CRM or CP8-CR

228 he disease are currently available, although passive immunization with C. parvum-specific antibodies

229 ly, studies in these same mice indicate that passive immunization with certain anti-Abeta antibodies

230 Passive immunization with chicken IgY has long served as

231 In primates, passive immunization with combinations containing human

232 Finally, passive immunization with CPS6-IgG1-E345K protected mice

233 studies were designed to compare active and passive immunization with DeltagD-2 versus an adjuvanted

234 Passive immunization with each antiserum significantly l

235 Passive immunization with either MAb 5C11 or 3E65 partia

236 Passive immunization with gammaDPGA mAbs protected >90%

237 Passive immunization with Guy's 13 prevents bacterial co

238 Passive immunization with hepatitis B surface antibody (

239 on and survival) was completely abrogated by passive immunization with high-titer human anti-MV antib

240 Passive immunization with Hla-specific antisera or activ

241 Anti-HIV passive immunization with human neutralizing monoclonal

242 We and others have previously shown that passive immunization with human nMAbs protected adult or

243 AIDS, the potential of pre- and postexposure passive immunization with hyperimmune serum to prevent o

244 llenging with the immunizing antigen, and by passive immunization with IgG or IgE anti-2,4,6-trinitro

245 Passive immunization with IgG1 and IgG2a mAb protected w

246 Passive immunization with immune (convalescent) serum co

247 roups of animals were given one prechallenge passive immunization with immune rabbit serum (IRS), M13

248 uire Ag in sensitized Ig-deficient mice, and passive immunization with immune serum or Ag-specific Ig

249 ministration of additional vaccine doses and passive immunization with long-acting monoclonal antibod

250 Passive immunization with MAb 3E65 was more effective in

251 Passive immunization with MAb 8E7 could significantly en

252 In wild-type mice, passive immunization with mAb against gp75 or active imm

253 Passive immunization with MAb MoPn-40 resulted in a lowe

254 Previously, we have demonstrated that passive immunization with monoclonal antibodies (MAbs) 4

255 Passive immunization with monoclonal antibodies (MAbs) s

256 Passive immunization with monoclonal antibodies (MAbs) t

257 (FnBPA) and fibronectin-binding protein B or passive immunization with monoclonal antibodies against

258 e to bind to the surface of M. tuberculosis, passive immunization with monoclonal antibodies directed

259 Passive immunization with monoclonal antibodies from hum

260 Passive immunization with monoclonal antibodies from hum

261 tion with recombinant PR (rPR) molecules and passive immunization with monoclonal antibodies reactive

262 tudies point out some potential drawbacks of passive immunization with monoclonal antibodies.

263 Passive immunization with monoclonal antibody TA99 targe

264 Challenge studies following passive immunization with neutralizing Abs suggest that

265 Passive immunization with neutralizing antibodies to IL-

266 pithelial neutrophil activating protein; (2) passive immunization with neutralizing antibodies to TNF

267 immunization with nontoxigenic Hla(H35L) or passive immunization with neutralizing monoclonal antibo

268 Passive immunization with plasma collected from convales

269 udy have implications for the improvement of passive immunization with polyclonal or monoclonal antib

270 Passive immunization with pooled sera from recombinant A

271 al challenge with P. yoelii sporozoites than passive immunization with purified IgG from rabbits immu

272 Passive immunization with rabbit antibodies against E. f

273 Active immunization with recombinant SasX or passive immunization with rabbit polyclonal anti-SasX Ig

274 ne mice challenged by transplantation and by passive immunization with sera from mice infected with e

275 amyloid peptide (Alphabeta) with vaccines or passive immunization with systemic monoclonal anti-Abeta

276 he aim of this study is to determine whether passive immunization with the 23-valent pneumococcal pol

277 Here we report that passive immunization with the broadly neutralizing antib

278 This study reports the effect of active or passive immunization with the conjugates or their antise

279 Passive immunization with the rabbit antisera resulted i

280 Importantly, passive immunization with the recombinant HBc-E2 particl

281 Our data indicate that passive immunization with this anti-Abeta monoclonal ant

282 Passive immunization with this antibody resulted in prot

283 e we show that the combination of active and passive immunization with vesatolimod may lead to higher

284 Passive immunizations with antisera targeting outer memb